coteauBeta Get App

ACAD

Acadia Pharmaceuticals Inc.
$20.31
+0.59% Oct 22 close
Health CareS&P 600 CompareTechnicals
1M3M6M1Y2Y
-12%+2%+16%+30%+44%Oct 2025Oct 2026Apr 2026
ACADSPY
1W
+3.0%
1M
-23.1%
3M
-18.2%
6M
-8.1%
YTD
-24.0%
1Y
-5.0%

Live chart

Loading live chart…

What they do

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

Healthcare · Biotechnology

For information only · Important disclosures

Grades vs sector

Momentum
20th percentile in sector
D
12-1 return: -11.2%
Percentile within its GICS sector across the S&P 1500.
Growth
74th percentile in sector
B+
Revenue growth (YoY): +16.4%
Percentile within its GICS sector across the S&P 1500.
Value
29th percentile in sector
D+
Forward E/P: 4.8% · EBITDA/EV: 4.1%
Percentile within its GICS sector across the S&P 1500.
Profitability
91st percentile in sector
A
Profit margin: +33.4% · Return on equity: +35.7%
Percentile within its GICS sector across the S&P 1500.
Revisions
Not enough data yet
–
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Systematic Models

Not held by any of our 5 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 Coteau Long Book
Not in the current book

News

More news
Acadia Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 4, 2026
Business Wire · Oct 21
Will Auvelity Continue to Aid Axsome's Top-Line Growth in Q3?
Zacks · Oct 21
ACADIA Pharmaceuticals Shares Fall After UBS Downgrade
MT Newswires · Oct 13
Top Midday Decliners
MT Newswires · Oct 13
Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects?
Zacks · Oct 13

Key stats

Market value$3.5B
P/E (last 12 months)9.1
P/E (next 12 months, estimated)21.9
52-week range$18.39 – $30.96
Revenue growth (latest quarter vs a year ago)+16.4%
Dividend yieldNo dividend
Analyst consensusBuy (19)
Average analyst price target$30.53 (+50%)
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

Earnings

Next report: 2026-11-04 · during market · EPS est 0.18
24-1125-0225-0525-0825-1126-0226-0526-080.000.86
EstimateActual (beat)Actual (miss)
ReportEPS estActualSurprise
2026-08-040.040.18+317.2%
2026-05-060.080.02-75.2%
2026-02-250.140.14-4.2%
2025-11-050.150.42+189.0%
2025-08-060.140.16+15.3%
2025-05-070.110.11+4.5%
2025-02-260.220.86+292.6%
2024-11-060.140.20+41.2%

Quarterly revenue

QuarterRevenueYoY
2026-06-30$308.0M+16.4%
2026-03-31$268.1M–
2025-12-31$284.0M–
2025-09-30$278.6M–
2025-06-30$264.6M–
Rating changes
Reiterated
2026-10-19 · Needham reiterated Buy on ACAD
Downgrade
2026-10-13 · UBS downgraded ACAD from Buy to Neutral
Reiterated
2026-10-08 · RBC Capital reiterated Outperform on ACAD
Reiterated
2026-09-25 · Deutsche Bank reiterated Buy on ACAD
Reiterated
2026-09-25 · HC Wainwright & Co. reiterated Buy on ACAD
Reiterated
2026-09-25 · Citizens reiterated Market Outperform on ACAD

Third-party analyst actions, not Coteau's views. All rating changes

Insider trades
Schneyer Mark C.
EVP, CHIEF FINANCIAL OFFICER · 2026-08-06
Sell
$272.6K
Schneyer Mark C.
EVP, CHIEF FINANCIAL OFFICER · 2026-08-06
Sell
$145.0K
Schneyer Mark C.
EVP, CHIEF FINANCIAL OFFICER · 2026-08-05
Sell
$169.6K
Thompson Elizabeth H.Z.
EVP, Head of Research & Dev · 2026-07-30
Sell
$1.3K
Thompson Elizabeth H.Z.
EVP, Head of Research & Dev · 2026-07-30
Sell
$431.4K

Stats refreshed 2026-10-21 18:22:37 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Free. Not investment advice. Unsubscribe anytime.

coteau

Free to use. No card, no ads, no auto-renew.

Independent research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Beta 0.9 · Oct 21, 2026